Rebate Reporting Law May Provide Timely Trigger For US Pricing Debate – In 2023
Executive Summary
Newly enacted requirement for US health plans to report granular drug price and rebating data to the government suggests that the great rebate debate of 2017-2020 won’t be over for long. The first public release of aggregated data will likely come in 2023 – and that might be when Congress is ready to take up drug pricing again.
You may also be interested in...
Drug Rebates, Impact On Premiums Must Be Disclosed Under COVID Stimulus Law
Medicare Part B payment loopholes also targeted in law, and Medicare Part D plans will need to offer real-time benefit tools for prescriber-patient decision making.
The Rebate Rule May Not Last, But It Changed The Pricing Debate
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill
Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry.